Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.78)
# 698
Out of 4,944 analysts
18
Total ratings
47.06%
Success rate
13.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.59 | +277.36% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $9.65 | +65.80% | 4 | Aug 12, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $8.35 | +43.71% | 2 | Jul 14, 2025 | |
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $105.24 | +10.22% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.52 | +155.68% | 2 | Jun 18, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $3.99 | +175.69% | 2 | May 19, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.46 | +1,429.72% | 1 | Jan 10, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.36 | +441.04% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $0.84 | +1,096.89% | 1 | Dec 5, 2024 |
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.59
Upside: +277.36%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $9.65
Upside: +65.80%
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $8.35
Upside: +43.71%
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $105.24
Upside: +10.22%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.52
Upside: +155.68%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $3.99
Upside: +175.69%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.46
Upside: +1,429.72%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.36
Upside: +441.04%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $0.84
Upside: +1,096.89%